KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Enterprise Value (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Enterprise Value for 8 consecutive years, with -$299.5 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 2.16% to -$299.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$299.5 million through Dec 2025, down 2.16% year-over-year, with the annual reading at -$299.5 million for FY2025, 2.16% down from the prior year.
  • Enterprise Value hit -$299.5 million in Q4 2025 for Castle Biosciences, down from -$287.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$225.5 million in Q2 2023 to a low of -$407.0 million in Q1 2021.
  • Historically, Enterprise Value has averaged -$285.8 million across 5 years, with a median of -$275.5 million in 2025.
  • Biggest five-year swings in Enterprise Value: crashed 312.54% in 2021 and later increased 26.76% in 2022.
  • Year by year, Enterprise Value stood at -$329.6 million in 2021, then grew by 21.54% to -$258.6 million in 2022, then rose by 6.0% to -$243.1 million in 2023, then dropped by 20.58% to -$293.1 million in 2024, then dropped by 2.16% to -$299.5 million in 2025.
  • Business Quant data shows Enterprise Value for CSTL at -$299.5 million in Q4 2025, -$287.6 million in Q3 2025, and -$275.9 million in Q2 2025.